Areterna

Areterna is a specialized tools and raw materials company powering the next generation of cell and gene therapies, particularly in the mRNA and in vivo CAR-T space. As a subsidiary of China's Synthgene Biotechnology, it leverages its parent company's deep expertise in nucleic acid chemistry, scalable GMP manufacturing, and an AI-assisted discovery platform to debottleneck the supply chain for therapeutic developers. The company is commercial-stage, generating revenue through the sale of its extensive product catalog and contract services, while also developing its own pipeline of low-cost animal mRNA vaccines for out-licensing.

Provider of nucleic acid raw materials, reagents, kits, and services for mRNA/oligo therapeutic development. Leverages parent company's AI-assisted discovery for novel cap analogs, expertise in nucleic acid chemistry, and GMP manufacturing.

Areterna competes in the mRNA/oligo raw materials space against large life science tools companies (e.g., Thermo Fisher Scientific, Merck KGaA) and specialized CDMOs/biotech suppliers (e.g., TriLink BioTechnologies, Aldevron, NEB). Differentiation is based on product breadth, quality (GMP, DMFs), focus on in vivo CAR-T tools, and cost-effectiveness.